Salute e Benessere
Lateral Flow Assays Market to Soar to $17.44 Billion by 2033 Amid Robust 6.98% CAGR - Grand View Research
Technological innovation is another key growth driver for the market. Advancements in assay design, signal amplification, and digital integration have enhanced the sensitivity, specificity, and functionality of LFAs. The introduction of smartphone-compatible devices, cloud connectivity, and multiplexing technologies has enabled real-time data analysis and broadened diagnostic applications. A notable example is Abingdon Health plc's launch of Boots' own-brand saliva-based pregnancy self-test in 2024, which marked a shift from conventional urine-based formats to non-invasive, saliva-based diagnostics. This innovation demonstrates how improved assay design is enhancing user convenience, accessibility, and accuracy in home-based testing.
While the LFA market continues to advance rapidly, it faces manageable challenges related to regulatory compliance, performance consistency, and manufacturing efficiency. Regulatory authorities such as the USFDA and EMA uphold stringent standards to ensure diagnostic accuracy and consumer safety, which in turn encourage continuous product improvement and innovation. Although variations in sensitivity and specificity may arise depending on assay design and sample type, ongoing research and the adoption of advanced detection technologies are helping minimize these issues. As a result, these challenges are driving companies to enhance assay reliability, accelerate approval timelines, and strengthen trust in point-of-care diagnostics.
Grand View Research has segmented the global lateral flow assays market based on product, application, technique, end use, and region:
• The global cell-based assays market size is expected to reach USD 28.56 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests.
• The global oxidative stress assay market size is anticipated to reach USD 2.09 billion by 2030 and is projected to grow at a CAGR of 9.43% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of oxidative stress-associated diseases such as cardiovascular diseases, respiratory diseases, diabetes, and others and research & development activities related to these diseases are major factors contributing to the market growth. For instance, according to the U.S. Department of Health and Human Services, in 2021, the global prevalence of diabetes among 20- to 79-year-old people was estimated at around 536.6 million, and it is expected to reach 783.2 million by 2045.
• The global immunofluorescence assay market size is anticipated to reach USD 4.95 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to reach at a CAGR of 5.29% from 2023 to 2030. Immunofluorescence is a traditional technique used for getting insight into cellular processes and structures using microscopy. For instance, specific proteins can be assessed for their location and expression. Increasing prevalence of chronic and infectious diseases, significant applications of immunofluorescence assay (IFA) in several areas and technological advancements in techniques and associated instruments are key factors driving the market growth.
• The global cell viability assays market size is expected to reach USD 3.01 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.94% from 2023 to 2030. The rising prevalence of chronic and infectious diseases and the increasing focus on cell-based therapeutics are expanding the growth prospects of the market. In addition, growing funding for cell-based research and increasing use of automated instruments are the key factors driving the market for cell viability assays (CVAs).
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco , the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Explore – The world's most expansive market intelligence platform developed by Grand View Research. Gain insights from 30K+ Global & Regional Reports, 120K+ Country Reports, 1.2M+ Market Statistics, 200K+ Company Profiles, and 5 business solutions encompassing ESG and Sustainability Consulting, Procurement Intelligence, Pricing Index and Analysis, and Consumer Analytics.
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Blog: https://globalindustryherald.com/
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lateral-flow-assays-market-to-soar-to-17-44-billion-by-2033-amid-robust-6-98-cagr---grand-view-research-302627506.html